Skip to main content

REVIEW article

Front. Psychiatry
Sec. Psychopharmacology
Volume 15 - 2024 | doi: 10.3389/fpsyt.2024.1496986

A systematic review and meta-analysis of the effects of combined aripiprazole on glycolipid metabolism in schizophrenia

Provisionally accepted
Sun Junwei Sun Junwei *Wei Tianbao Wei Tianbao Jiang Limei Jiang Limei Zhang Ruilin Zhang Ruilin Sun Hang Sun Hang Sun Zhenjie Sun Zhenjie
  • Shanxi Medical University, Taiyuan, China

The final, formatted version of the article will be published soon.

    Background: Current research on aripiprazole adjunct therapy suggests potential benefits in improving psychiatric symptoms and metabolic disorders in patients with schizophrenia. However, the evidence remains limited due to the scarcity of research and a lack of detailed analysis on glucose and lipid metabolism indicators. This study aims to systematically review and analyze randomized controlled trials (RCTs) to evaluate the effects of aripiprazole combination therapy on both psychiatric symptoms and glycolipid metabolism.A systematic search of PubMed, EMBASE, and Web of Science databases was conducted to identify randomized controlled trials (RCTs) investigating the impact of aripiprazole combination therapy on glycolipid metabolism and clinical symptoms.Results: Adjuvant treatment with aripiprazole reduced blood glucose, triglycerides, total cholesterol, and LDL levels in patients with schizophrenia, but had no significant effect on HDL levels. In addition, the study results showed a significant improvement in metabolic parameters at short-term (≤ 8 weeks) and dosing doses >15 mg. However, aripiprazole adjuvant therapy may lead to worsening of clinical symptoms, so caution is required when using it clinically.Conclusions: Aripiprazole adjunct therapy shows potential benefits in improving both psychiatric symptoms and metabolic parameters, but more comprehensive research is needed to solidify these findings, particularly regarding glycolipid metabolism indicators.

    Keywords: Schizophrenia, aripiprazole, combination therapy, Glucolipid metabolism, review

    Received: 16 Sep 2024; Accepted: 11 Dec 2024.

    Copyright: © 2024 Junwei, Tianbao, Limei, Ruilin, Hang and Zhenjie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Sun Junwei, Shanxi Medical University, Taiyuan, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.